Compare
Cognex Corp vs Ralliant Corp vs MKS Inc vs Mesa Laboratories Inc
| Latest fiscal year | Cognex Corp CGNX | Ralliant Corp RAL | MKS Inc MKSI | Mesa Laboratories Inc MLAB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $994.36M | $2.07B | $3.93B | $249.13M |
| Revenue growth (YoY) | +8.7% | -4.0% | +9.6% | +3.4% |
| Gross margin | 66.9% | 50.3% | 46.7% | 63.5% |
| Operating margin | 16.3% | -57.2% | 13.4% | 7.4% |
| Net margin | 11.5% | -59.1% | 7.5% | 2.7% |
| Net income | $114.44M | -$1.22B | $295.00M | $6.71M |
| EPS (Diluted) | $0.68 | -$10.84 | $4.37 | $1.21 |
| Operating cash flow | $245.51M | $397.60M | $645.00M | $42.83M |
| Free cash flow | $236.77M | $358.40M | $497.00M | $39.58M |
| Cash & equivalents | $262.93M | $318.80M | $418.00M | $26.93M |
| Total assets | $2.02B | $3.82B | $8.80B | $427.75M |
| Total liabilities | $524.65M | $2.19B | $6.08B | $241.50M |
| Shareholders' equity | $1.49B | $1.63B | $2.72B | $186.25M |
| Return on year-end equity | 7.7% | -74.8% | 10.8% | 3.6% |
| Shares outstanding | 167.00M | 112.90M | 67.20M | 5.52M |
Revenue, most recent five fiscal years
| Fiscal year | Cognex Corp | Ralliant Corp | MKS Inc | Mesa Laboratories Inc |
|---|---|---|---|---|
| Latest | $994.36M Ended 2025-12-31 | $2.07B Ended 2025-12-31 | $3.93B Ended 2025-12-31 | $249.13M Ended 2026-03-31 |
| 1 year earlier | $914.51M Ended 2024-12-31 | $2.15B Ended 2024-12-31 | $3.59B Ended 2024-12-31 | $240.98M Ended 2025-03-31 |
| 2 years earlier | $837.55M Ended 2023-12-31 | $2.16B Ended 2023-12-31 | $3.62B Ended 2023-12-31 | $216.19M Ended 2024-03-31 |
| 3 years earlier | $1.01B Ended 2022-12-31 | n/a | $3.55B Ended 2022-12-31 | $219.08M Ended 2023-03-31 |
| 4 years earlier | $1.04B Ended 2021-12-31 | n/a | $2.95B Ended 2021-12-31 | $184.34M Ended 2022-03-31 |